Market Overview

Progressive Care Integrates with Illinois Cancer Specialists to Join The US Oncology Network

Share:

More patients in suburban Chicago will benefit from the combined
expertise and resources

Illinois
Cancer Specialists
(ICS), an affiliate of The
US Oncology Network
(The Network), announced today that Progressive
Care has joined its practice. The combined practice will continue to
offer comprehensive, state-of-the-art cancer care in its nine
convenient, patient-friendly community settings throughout suburban
Chicago. ICS has been a part of The US Oncology Network, one of the
nation's largest networks of integrated community-based oncology
practices, for several years.

"The Network will benefit greatly from the addition of these experienced
oncology care providers," said Marcus Neubauer, M.D., chief medical
officer. "I am looking forward to collaborating with them as part of our
larger organization in the Chicago area."

"We're honored to welcome the physicians and staff from Progressive Care
to our practice," said David Hakimian, M.D., ICS practice president.
"This integration brings Chicagoland patients access to 22 physicians in
nine of their local communities, giving them confidence that they're
getting the expertise, resources and teamwork they want and need when
facing cancer."

Clinical teams will be integrated to leverage expertise and tools that
drive value-based care, and employ the latest technologies and drug
therapies to ensure that patients receive high-quality care in a
convenient setting. ICS treatment centers feature outpatient treatment
and diagnostic facilities including chemotherapy, radiation therapy,
positron emission tomography, computerized tomography, stem-cell
transplant, clinical research, laboratory, x-ray studies and specialty
pharmaceuticals.

"The physicians of Progressive Care have been dedicated to bringing the
latest innovations to cancer care for more than 26 years," said Mark
Karides, M.D., Progressive Care practice president. "By coming together
with ICS, we are able to advance cancer care even further while
maintaining our focus on the compassionate, personalized patient care
for which we are known throughout our community."

By joining ICS, Progressive Care physicians can also collaborate with an
expanded physician community of more than 1,400 oncologists in The US
Oncology Network. As members of The Network, providers share expertise
and best practices through committees, workshops, conferences and via
The Oncology Portal, a secure online portal where physicians can share
data and collaborate on complex cases. Progressive Care physicians will
also be able to utilize Value Pathways, the evidence-based treatment
guidelines developed by physicians and clinicians in The Network
together with the National Comprehensive Cancer Network® (NCCN®) and
other tools and technologies.

About Illinois Cancer Specialists

Illinois Cancer Specialists is dedicated to providing convenient,
compassionate and leading-edge cancer care to patients in Chicago and
the surrounding areas. With more than 20 physicians and nine locations,
ICS brings patients advanced cancer care, along with the tools,
resources and support they need to help them through their cancer
journey. ICS is proud to offer more: more physician collaboration, more
clinical trials and more convenient locations. Find out how patients are
a priority at Illinois Cancer Specialists, by visiting www.IllinoisCancerSpecialists.com.

Illinois Cancer Specialists is an affiliate of The US Oncology Network.
This collaboration unites ICS with more than 1,400 independent
physicians dedicated to delivering value-based, integrated care for
patients — close to home. Through The Network, these independent doctors
come together to form a community of shared expertise and resources
dedicated to advancing local cancer care and to delivering better
patient outcomes. The US Oncology Network is supported by McKesson
Specialty Health
, whose coordinated resources and infrastructure
allow doctors in The Network to focus on the health of their patients,
while McKesson focuses on the health of their practices. ICS also
participates in clinical trials through US
Oncology Research
, which has played a role in more than 70
FDA-approved cancer therapies, approximately one-third of all cancer
therapies approved by the FDA to date. For more information, visit www.usoncology.com.

View Comments and Join the Discussion!